Abstract

Sandhoff’s disease is a rare autosomal recessive disorder of sphingolipid metabolism that results from deficiency of the lysosomal enzymes, β-hexosaminidase A and B. The resultant accumulation of GM$_2$ ganglioside within both grey matter nuclei and myelin sheaths of the white matter results in eventual severe neuronal dysfunction and neurodegeneration. Disease progression is rapid, resulting in early death. Currently, there is no curative treatment, with therapy remaining primarily supportive.

This case report is of a 13-month-old aboriginal Canadian boy who was referred for further investigations related to global developmental delay and loss of developmental milestones, at which time the diagnosis was discovered.

Clinical presentation

A 13-month-old Canadian aboriginal boy presented with global developmental delay and loss of developmental milestones. He was born at 38 weeks to nonconsanguineous parents after an uncomplicated pregnancy. He experienced normal development until the age of 3 months, at which time-delayed motor skills, followed by episodes of myoclonic jerks, were observed. Verbal and social development was normal until approximately 6 months of age.

Physical examination was remarkable for increased head circumference relative to weight, with frontal bossing and hypotonic, nondysmorphic facies. No organomegaly was present. Neurological examination revealed central hypotonia with head lag and symmetric spasticity involving all four limbs. Deep tendon reflexes were normal, with the exception of ankle clonus and upgoing plantar reflexes. Bilateral macular cherry red spots were visualised, and visual evoked responses were absent. Further investigations including routine bloodwork and metabolic studies were normal. An EEG showed excessive slowing of delta frequencies associated with drowsiness. Plasma hexosaminidase levels were significantly decreased.
Diagnosis

The diagnosis was infantile onset Sandhoff’s disease.

Radiographic findings

Bilateral, diffuse, T1 hyper-, T2 (Figs 1 and 2) and FLAIR hypointense (not shown) thalami were seen. Hyperintense, speckled-appearing putamina on T2W images containing punctate T2 and FLAIR hypointense foci are demonstrated in Fig. 1. Additional MRI findings include a delayed myelination pattern for age, with no visible areas of diffusion restriction.

Single voxel stimulated echo acquisition mode (STEAM) acquisition of the right lentiform nucleus for magnetic resonance spectroscopy revealed diminished N-acetylaspartate (NAA), suggestive of neuronal loss/dysfunction (Fig. 4). Multivoxel acquisition through deep grey matter structures revealed diffusely diminished NAA, most notable within the thalami (not shown). Choline levels were found to be elevated which, while a nonspecific finding, may relate to dysmyelination. A few, small, nonspecific lactate peaks were also seen.

Discussion

Sandhoff’s disease is a rare autosomal recessive disorder of sphingolipid metabolism, with an incidence of 1 in 384 000 live births, related to a genetic deficiency of the enzyme β-hexosaminidase. Two catalytically active forms of this enzyme exist: β-hexosaminidase A, composed of one α and one β subunit, and β-hexosaminidase B, which contains two β subunits. The gene HEXA encodes the α subunit, and mutations affecting this gene result in a deficiency of β-hexosaminidase A, clinically known as Tay-Sachs disease. In Sandhoff’s disease, both β-hexosaminidase A and B have been found to be deficient secondary to mutations within the HEXB gene which encodes the common β subunit. Clinically, these two genetic disorders are indistinguishable from each other.

β-hexosaminidase is a lysosomal enzyme responsible for degrading the ganglioside GM₂ to GM₁ by removing the β-N-acetylgalactosamine residue from the nonreducing terminal of the GM₂ ganglioside. In Sandhoff’s disease, total hexosaminidase activity is reduced to less than 2 - 3% of normal, unlike Tay Sachs, where total hexosaminidase activity is preserved due to functional β-hexosaminidase B activity. However, the B isoenzyme is unable to hydrolyse the GM₂ ganglioside, which accumulates in the brain and also within the liver, spleen, and kidneys, which may become enlarged.

Gangliosides have been found to be present primarily within grey matter nuclei and, to a lesser degree, within myelin sheaths of the white matter. GM₂ ganglioside accumulation within lysosomes of cortical neurons results in distension of neuronal cell bodies and nucleus displacement. Over time, this cellular enlargement results in neuronal dysfunction and severe neurodegeneration from eventual neuronal loss. Neuronal deterioration and death results in cortical atrophy with widened sulci, narrowed gyri, dilated ventricles and atrophy of the optic nerves and cerebellum. Ganglioside storage has been found to induce degeneration of white matter. Pathologically, there is evidence for demyelination as well as delayed myelination, which is believed to be secondary to the grey matter disease. At autopsy, lipid storage and oedema have been found within the white matter.

While the biochemical basis of Sandhoff’s disease is well understood, the exact aetiology resulting in neuronal death and cerebral atrophy is yet to be elucidated. Animal models have sug-
The clinical expression of Sandhoff’s disease is variable. The classic infantile form is characterised by an onset between 3 and 9 months of age,1,16,18 following initial normal development. Clinical manifestations are variable and may include initiation of a pronounced startle response after 3 or 4 months of age.5,17 Previously acquired developmental milestones decline, and severe muscular hypotonia, followed by spastic quadraparesis and seizures, are additional features.16,18 Macular cherry red spots are occasionally observed,17,18 though this finding is non-specific and also seen in several other lysosomal storage disorders. Disease progression is rapid, resulting in death by 3 to 5 years of age. Currently, there is no curative treatment and therapy remains supportive.18

The juvenile/subacute variant often presents with ataxia between 2 and 5 years of age,19 and has a slowly progressive course and more favourable prognosis.1,2 The adult/chronic subtype generally presents in the second or third decade of life, with a variable clinical picture of either spinocerebellar degeneration or motor neurone disease20 and typically has a fair survival rate.1,2,19

**Imaging**

Although Sandhoff’s disease has been traditionally considered to be a grey matter disease, neuroimaging studies have characterised abnormalities within both the white and grey matter of Sandhoff patients. Despite extensive variability in findings among studied patients, bilateral symmetric thalamic changes have been found to be an early, predictable finding that is probably specific to the GM$_1$ gangliosidoses, such as Sandhoff’s disease, and may be useful in determining whether to perform more specific investigations in infants suspected of having a neurodegenerative disease.5,17 The thalamai are usually homogeneously hypeintense on computed tomography (CT)5,14,17,20 and T2 hypointense13,12,20 and T1 hyperintense13,12,20 on magnetic resonance imaging (MRI). MR findings have been found to be particularly variable within the caudate nucleus, globus pallidus, and putamen, though these structures have been shown to be T2-hyperintense.17

Currently, there are several theories as to how the stored sphingolipids affect neuroimaging. Abnormal accumulation of macromolecules or lipids increases tissue viscosity and shortens T2 relaxation time, manifesting as a decreased T2 signal, explaining the MR findings among Sandhoff patients. Proton magnetic resonance spectroscopy (MRS) has revealed progressive elevation in myoinositol (mI):Cr ratios13,18 within white matter, grey matter, and the thalamus.13 As the mI peak signifies glial cell activity, it has been hypothesised that accumulation of GM$_2$ gangliosides results in glial cell proliferation, or reactive gliosis.12 Demyelination in Sandhoff’s disease is expected as a consequence of neuronal loss although, despite clinical and radiographic deterioration, Cho/Cr ratios have been found to remain normal.12,18

It is thought that the accumulation of gangliosides within cell membranes results in a relative reduction of Cho precursors, thus minimising MRS evidence of demyelination.12

NAA and N-acetylaspartylglutamate (tNAA) are markers of neuroaxonal integrity and have been found to decline with neuronal damage and loss.12,23,26 Progressive declines in NAA and tNAA, consistent with neuronal loss, have been observed in Sandhoff patients.13,19

Sandhoff’s disease is characterised by the accumulation of N-acetylsphingosine-containing oligosaccharides, both within glycosphingolipids and as free oligosaccharides, both of which contain N-acetyl moieties.13,19 Further analysis has revealed that it is the level of stored glycosphingolipids, and not the level of cerebral oligosaccharides, that correlates with disease severity.19 Both animal and human data have confirmed a new spectrum adjacent to the tNAA resonance with a resonance frequency of approximately 2.07 ppm which has been assigned to the N-acetyl moiety of N-acetylsphingosine (NAHex).13,14,20 Human data have shown this resonance to be most prominent in white matter and the thalamus and, to a lesser degree, within paramedian parietal grey matter, though this was not seen within the basal ganglia.19 This resonance is believed to relate directly to the pathophysiology of Sandhoff’s disease by suggesting that oligosaccharides containing NAHex accumulate in cortical and subcortical grey matter as well as in white matter.19 Animal proton MRS studies have demonstrated consistently higher intensities of N-acetyl resonances than controls, and have also shown a progression of increasing intensity of these resonances from presymptomatic conditions.
to terminal disease stages. This presumptomatic NAHex resonance has yet to be demonstrated within presymptomatic Sandhoff patients.

Knowledge of the existence of the NAHex resonance may be of direct clinical relevance in the future as the use of MRS broadens to include both non-invasive diagnostic and treatment strategies. This approach may also be helpful in evaluating potential experimental strategies in the treatment of this and other disorders of lysosomal storage as well as in helping to monitor disease progression.

References: